Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary
February 25, 2021
Earnings Call Speaker Segments
Oliver Maier
executiveThanks a lot, Haley. Good afternoon, and thank you everyone for being with us today. I want to welcome all of you to our conference call covering the full year 2020. Joining me today are Werner Baumann, our CEO, and Wolfgang Nickl, our CFO. As usual, the businesses are represented by the management board members responsible for them. Stefan Oelrich is here for Pharma. Liam Condon represents Crop Science, and Heiko Schipper is with us for Consumer Health. Werner will kick off today's call with a look at the key developments, how the divisions performed, and the strategic outlook, after which Wolfgang will walk through the full-year financials and the outlook for 2021, and then we'll open things up for the Q&A session. As always, I'd like to begin today's call by pointing you to the cautionary language contained in our safe harbor statement and in all the materials we've distributed today. With that, Werner, over to you.
Werner Baumann
executiveOkay, thank you, Oliver, and good afternoon, everyone. I'm glad to have you join our conference call today as well. Let me begin by noting that the previous year was truly unprecedented in a number of ways. A pandemic of a kind seen once in a century is still impacting our businesses, our employees, and the lives of our families. We truly rose to the occasion as a company, as a dependable partner, and as a solid corporate citizen. I feel a great deal of pride in the remarkable engagement and the contributions made by our 100,000 people across the globe in assisting wherever possible. That is what we stand for, and so does our vision, "Health for all and hunger for none." In keeping with that vision, we recently also formed a partnership with CureVac for developing and producing their vaccine candidate, to help in the fight against the pandemic as quickly as we can. Secondly, our businesses have shown themselves to be robust and resilient in spite of headwinds stemming from the pandemic, regulatory challenges, and adverse currency effects. Within Pharmaceuticals, restrictions related to COVID-19 brought about a lower volume of elective treatments, particularly in our ophthalmology, women's health, and radiology businesses. Tighter hygiene and protection measures likewise put pressure on demand for our cough and cold products in Consumer Health.
Werner Baumann
executiveConversely, increased attention to prevention and self-care proved beneficial for our Nutritionals business. In addition, significant weakening of key currencies such as the Brazilian real hurt us, with Crop Science operations especially affected. As a way of offsetting both softer growth and currency headwinds overall, we concentrated on what lay within our own control, speeding up our efficiency initiatives and applying rigorous cost management steps. Third, in order to prepare the ground for future growth, we have successfully brought to maturity our late-stage Pharmaceuticals pipeline with Nubeqa, VERQUVO — the brand name for vericiguat — and finerenone. We likewise stepped up external sourcing of innovative assets and acquired businesses in cell and gene therapy, in women's health, and in personalized nutrition. In addition, we wrapped up our announced portfolio measures through the sale of our Animal Health business, and we reset the asset base of our Crop Science business with the required non-cash impairment charges at the end of September. At that time, we also stated that we would examine additional divestments of businesses below the division level. With that in mind, yesterday we announced the plan to divest our Environmental Science Professional activities, and we will keep assessing other divestiture options. Allow me also to give you a brief update on our litigations.
Werner Baumann
executiveEarly in February, we announced and filed a revised agreement with counsel for the plaintiffs on a plan aimed at managing and resolving upcoming Roundup cases. That new agreement is now awaiting court review and approval. We're also still negotiating with the plaintiffs' counsel to reach agreements covering the rest of the current cases. Roughly 90,000 claims within the Roundup litigation overall fall under settlement agreements that have been executed, are in process, or failed to satisfy eligibility requirements and were disqualified. I'd also like to take this moment to welcome Sarena Lin to the team. Sarena was appointed to the Board of Management on February 1st as our Chief Transformation and Talent Officer. Driving the company's transformation will be a pivotal part of her role. Lastly, at our upcoming virtual Capital Markets Day on March 10th and 11th, we'll share strategy updates for the group and our divisions, along with our midterm targets. A great deal has been accomplished, and I'm especially pleased to report that we hit our updated guidance based on currency rates as of month end September, even with further currency deterioration over the remainder of the year. The right column displays the as reported full-year figures, with solid check marks across the board.
Werner Baumann
executiveOn a currency- and portfolio-adjusted basis, sales rose 1%, reaching EUR 41.4 billion. Group adjusted EBITDA margin climbed 140 basis points, hitting 27.7%, while core EPS held steady at EUR 6.39. Free cash flow totaled EUR 1.3 billion, a figure affected by settlement payouts. In fact, it exceeded our adjusted guidance, helped by robust operational cash generation, which likewise helped bring net financial debt down to €30 billion. For fiscal 2020, we are proposing a dividend of EUR 2 per share, pending approval at the AGM. At roughly 31%, the payout ratio sits inside the 30%-40% target corridor relative to our core EPS. Now I'll move on to how our businesses performed, beginning with Crop Science. Sales adjusted for currency and portfolio effects increased 1%, powered by strong results in Latin America and Asia Pacific, each up 9% and offsetting a 4% decrease in North America. That North American decrease stemmed largely from shifts in corn demand, greater competitive pressure in soybean, and the temporary loss of the XtendiMax registration. With the new EPA registration for our XtendiMax herbicide in late October, we have now obtained every required state registration.
Werner Baumann
executiveGlobally, corn sales came in roughly flat, since growth across every other region almost canceled out the North American decreases. In a similar way, Intacta's very strong sales growth in Latin America more than made up for soybean declines in North America, producing modest overall growth worldwide. Our fungicide platform kept up its strong upward trajectory, and every region contributed to a 9% rise in sales on a currency- and portfolio-adjusted basis. In particular, sales got a positive push from the ongoing upgrade to Fox Xpro in Brazil, from more favorable weather in North America, and from synergy effects tied to the combined product offering. Our Environmental Science business likewise posted strong growth in all regions, up 12% on a currency- and portfolio-adjusted basis. Our vegetable seeds business dropped 4% year-on-year, as our North American operation faced lower demand related to COVID. Even though sales increased, Crop Science EBITDA before special items fell 4% to EUR 4.5 billion. Favorable cost management and synergy contributions were outweighed by enormous adverse currency effects totaling EUR 540 million. Let's turn now to Pharmaceuticals. Sales declined 2% on a currency- and portfolio-adjusted basis, to EUR 17.2 billion in 2020, driven chiefly by the COVID-19 pandemic's effect on elective treatments, as described earlier.
Werner Baumann
executiveOn top of that, the second round of the volume-based procurement policy took effect in April in China, and it weighed heavily on pricing for our AVELOX and Glucobay products all year long, driving a pronounced decline in top-line results that volume gains only partly offset. Xarelto, our best-selling product, kept up its strong growth path, rising 12% in 2020 on a currency-adjusted basis. Even with the top-line shortfall and negative currency effects, EBITDA before special items climbed 3% to EUR 6 billion, lifting our margin by 230 basis points to roughly 35%, helped by disciplined expense management, including some non-recurrent savings and about EUR 150 million in milestone income from Adempas. We're very enthusiastic about how our late-stage pipeline is progressing. For Verquvo, we obtained FDA approval in January. Verquvo is the first approved soluble guanylate cyclase stimulator indicated for symptomatic chronic heart failure. Finerenone, our therapy for patients with chronic kidney disease and type 2 diabetes, was granted priority review by the FDA in January. In addition, BlueRock Therapeutics, which began as a Leaps by Bayer investment, got FDA clearance to start a phase I study in patients with advanced Parkinson's disease. Through the acquisition of KaNDy Therapeutics, we have brought a novel, phase III-ready, non-hormonal development candidate for menopause management into our women's health business.
Werner Baumann
executiveThrough the AskBio acquisition, we further bolstered our technology and pipeline footprint as well. Together with BlueRock Therapeutics, we created a cell and gene therapy platform plus certain clinical assets aimed at developing breakthrough, innovative treatments for patients. We wrap up the divisional updates with Consumer Health, which delivered strong 5% sales growth in 2020 across every region on a currency- and portfolio-adjusted basis. That came from significant momentum in our Nutritionals business, which rose 23% on sustained demand for preventive health solutions. Meanwhile, a big flu season and softer demand for our cough and cold products produced a 4% decline in our allergy and cold category, even as our allergy products kept growing. Our clean EBITDA margin rose 110 basis points to 22% in 2020, fueled by accelerated growth and contributions from the efficiency programs. EBITDA before special items fell by 3%. Roughly EUR 180 million in negative currency and portfolio effects versus prior year are masking the very good underlying business performance. Before Wolfgang provides more details on 2020 and our financial guidance for 2021, I will offer some closing perspectives. To set the stage for future growth, we will build on our strength and focus on factors within our control while navigating macro dynamics.
Werner Baumann
executiveWhen it comes to Crop Science, we hold the top market position, with profitability and a pipeline that lead the industry. In fact, we're cautiously optimistic regarding the positive market conditions now emerging, since corn and soybean commodity prices have improved considerably since September, and should that hold, it ought to have a favorable effect on our business. We'll share updates as we progress through the quarters ahead. Turning to Pharmaceuticals, our focus stays on getting the most value from our blockbusters, XARELTO and EYLEA. Naturally, we're getting ready for successful launches of VERQUVO and finerenone, along with a broader rollout of Nubeqa. Our Consumer Health business will sharpen its focus on growth that is sustainable, profitable, and above market, powered by our robust brand portfolio and the recent addition of Care/of. Looking more broadly, past our own operations, the pandemic is plainly nowhere near finished. It will keep affecting markets and, in time, our business as well. Given that situation, we're delighted to contribute by supplying vaccines through our collaboration with CureVac and the recent news that we will begin vaccine manufacturing still in 2021. As for where we stand now and our guidance, we do anticipate positive growth momentum across every one of our businesses. With that said, I'll pass things over to Wolfgang.
Wolfgang Nickl
executiveThanks, Werner. And hello to everyone joining us as well — a very warm welcome from my side too. What I'll do now is take you through a few more financial specifics for 2020, and after that I'll cover the outlook for fiscal 2021. Sales for the group came to EUR 41.4 billion, while EBITDA before special items matched the previous year's figure of EUR 11.5 billion. One thing worth flagging: currency movements weighed heavily year on year on both sales — to the tune of EUR 1.9 billion — and on EBITDA before special items, by approximately EUR 740 million. Core earnings per share were essentially unchanged at EUR 6.39, and our core tax rate edged up to 23.7% from 22.5% in 2019. I should also mention that the FX impact on core EPS came to EUR 0.53 in 2020. So on a constant-currency basis, we'd have finished at EUR 6.92 — nearly reaching the original guidance range of EUR 7 to EUR 7.20, even with the pandemic. Free cash flow came in above our adjusted guidance, landing at EUR 1.3 billion in 2020, thanks to robust operational cash generation. That figure includes payouts tied to litigation settlements of about EUR 3.8 billion. On an operational basis, we surpassed the 2019 level of EUR 4.2 billion through disciplined working capital and CapEx management.
Wolfgang Nickl
executiveStarting from the EUR 6.39 core EPS for continued operations that I just referenced, the bridge to reported EPS from continued and discontinued operations begins there. As we typically do, the first adjustment is for acquisition-related amortization. On the chart, the impairment column shows a negative impact of EUR 9.31, which corresponds to non-cash impairment charges of roughly EUR 9.2 billion within our Crop Science business. That figure breaks down into approximately EUR 2.2 billion against goodwill and about EUR 7 billion against other intangible assets. EBITDA-relevant special items came in with a negative impact of EUR 14.63, mostly connected to litigation and settlement charges. The special items and the financial results are for the most part tied to the fair value of the Covestro and Elanco shares. As of today, all of our Covestro shares have been sold, and we continue to hold roughly 10 million Elanco shares. A positive tax effect on the sum of these items added EUR 3.72. Beyond that, there is an impact of EUR 5.17 from discontinued operations, chiefly from the gain on the sale of our Animal Health division. That does not offset the negative impact of the special items and impairment charges, which leaves a loss per share from continued and discontinued operations of EUR 10.68.
Wolfgang Nickl
executiveNow let's turn to the balance sheet. Net financial debt came down by approximately EUR 4 billion versus the prior year, landing at around EUR 30 billion, and that is considerably better than what we had guided to. The key factors driving that year-on-year reduction in net debt were free cash flow that beat expectations, the proceeds from divesting our Animal Health business, and, in this instance, a favorable currency impact. Those effects more than compensated for dividend payments totaling roughly EUR 2.8 billion as well as cash outflows tied to acquisitions including AskBio, KaNDy, and Care/of. One last point: approximately 45% of our financial debt is denominated in US dollars. At present, each percentage point of depreciation in the US dollar relative to the euro reduces our net financial debt by roughly EUR 130 million, and the reverse also holds. Turning now to how our businesses break down by region. It's worth reminding everyone that only around 20% of our net sales are denominated in euros, whereas approximately 40% of our costs are incurred within the Eurozone. As a result, euro appreciation puts negative pressure on our profit margin, with limited natural hedges available. In addition, group sales differ considerably by quarter and by region, driven in particular by the traits of our Crop Science business, given the differing planting cycles across the Northern and Southern hemispheres.
Wolfgang Nickl
executiveThis slide shows how important Europe and North America sales are during the first half of the year. Latin America sales, by contrast, lean heavily toward the second half. Since currency moves keep affecting our financial KPIs, I'll lay out the foreign exchange rate assumptions we're currently using for 2021. Take the US dollar as an example. In the first half of 2020, the average exchange rate was about $1.10 per EUR. By the end of 2020, it was $1.23 per EUR — a depreciation of roughly 10%. So if rates stay at 2020 year-end levels, that negative US dollar trend is expected to weigh heavily on the first half of 2021. At the bottom of the slide, you can see the net impact of the strong EUR appreciation on our 2020 net sales, along with the estimated effect for 2021. For 2021, we expect negative currency headwinds of roughly EUR 1 billion in the first quarter alone, and EUR 2 billion for the full fiscal year, assuming currencies remain at 2020 year-end exchange rates. That matters because most of the sales in our crop business are made in the U.S.
Wolfgang Nickl
executiveDuring the first six months of the year, expect currency headwinds to hit our crop division especially hard. As a reminder, generally speaking, you can assume that a 1% change in the foreign currency basket versus the euro affects our net sales by roughly EUR 350 million and clean EBITDA by roughly EUR 100 million. Updates on our foreign exchange rate assumptions will be provided during our quarterly calls. With that in mind, I'd like to move to our guidance for 2021, which assumes constant currencies — put differently, average actual 2020 exchange rates. We expect Bayer Group sales to land in the range of EUR 42 billion-EUR 43 billion, an increase of around 3% on a currency and portfolio adjusted basis. Our EBITDA margin before special items is anticipated to stay at the prior year level of approximately 27%. For core EPS, we confirm our prior outlook and see a slight decline versus 2020. Accordingly, we expect core EPS in the range between EUR 6.10 and EUR 6.30, again at constant currencies. Free cash flow is expected in the range between minus EUR 3 billion and minus EUR 4 billion, including anticipated payouts for litigation settlements of approximately EUR 8 billion.
Wolfgang Nickl
executiveWe're forecasting net financial debt to rise to somewhere between EUR 36 billion and EUR 37 billion, mostly because of settlement payouts plus roughly EUR 2 billion for dividend payments. In the gray column, we show what currency effects would look like for fiscal year 2021 assuming currencies remained at 2020 year-end exchange rates. On our sales figure, that would work out to a negative currency impact of about EUR 2 billion, which is also shown on the earlier chart. Our EBITDA margin before special items would take a hit of roughly 70 basis points, and at year-end exchange rates our core earnings per share would come in about EUR 0.50 lower. At year-end exchange rates, the US dollar would produce a positive effect of roughly EUR 1 billion on our net financial debt in 2021. Our guidance mirrors our current business and incorporates no impacts from the planned divestment of our professional Environmental Science businesses. Turning to divisional guidance, currency and portfolio adjusted growth for Crop Science is now expected at around 2%, with an adjusted EBITDA margin of about 24% at constant currencies. We expect that growth to be driven mainly by fungicides, herbicides, corn, and cotton, partly offset by ongoing competitive dynamics in soybeans.
Wolfgang Nickl
executiveOn the Pharmaceuticals side, we're anticipating 4% CPA growth with a margin near 32%, supported by ongoing expansion of XARELTO and EYLEA along with our assumption that COVID-19 restrictions will ease. Then for Consumer Health, we're looking at roughly 2%-3% CPA growth and a margin in the 22% to 23% range, fueled by sustained momentum in Nutritionals, though we do expect cough and cold demand to soften. I'd also point out that the appendix of our investor presentation contains the other major KPIs we've listed. With that said, Oliver, I'll turn things back to you so we can begin the Q&A.
Oliver Maier
executiveThanks, Wolfgang. I really appreciate the overview. As usual, before we get started, I’d like to ask everyone to limit themselves to roughly two questions each. That way we can get to as many questions as possible, since we have quite a strong lineup within the time we’ve got. With that, Haley, please go ahead and open the lines for questions.
Operator
operatorThank you. Ladies and gentlemen, we're going to start the question-and-answer portion at this point. Should you have a question, kindly press star and then the one on your telephone keypad. In case you'd like to withdraw your request, press star and then the two. Today, if speaker equipment is what you're using, please lift the handset before you make your selection. Please hold a moment for the first question. Mr. Verdult is our first questioner. Kindly give your name, the name of your company, and then your question.
Peter Verdult
analystThanks a lot. This is Peter Verdult from Citi, with a couple of questions as requested. The first one is probably the obvious question everybody has raised this morning, and it may be for Liam: given the recent Crop dynamics, why is the guidance for Crop in 2021 only 2% growth? Is that conservatism, or is there something we're missing? That's the first question. On Pharmaceuticals, would you be willing to share the 2020 product sales for your recent launches? And can you remind us how you're thinking about Xarelto in China with respect to VBP pressures? Have you built anything into your assumptions, or is that more likely to come next year? Thank you.
Liam Condon
executiveThanks very much, Peter. On the crop question—which I agree is on everyone's mind—let me give you my take. My view of the year ahead is cautiously optimistic. The cautious part is because we're only just into the year. As for tailwinds, we clearly expect U.S. acreage to rise, likely 180 to 182 million acres across soybeans and corn, with the mix clearly tilted toward soybeans. In Brazil, we can expect better pricing as that market recovers, meaning we'll close the gap left by the FX devaluation we've seen and catch up on price. With commodity prices where they are, crop protection usage should probably be better as well, since farmers will want to protect their crops. All of that is genuinely good. On the headwind side, again it's clearly Forex, especially this year with the U.S. dollar, for a company like ours—Wolfgang already touched on that. And with COVID-19 it's still very early; we don't know how the year will unfold, and we don't want to call anything prematurely. Keep in mind that what's driving growth in the market at the moment is essentially higher demand coming out of China, and that stems from African swine fever.
Liam Condon
executiveSo essentially, what happened was the hog herd in China had now been wiped out, and soybean demand rose somewhat, along with corn demand to a degree, plus there's the professionalization of hog herd management in China. There's a possibility—we're seeing anecdotal reports of a fresh African swine fever outbreak in China. As of now, from everything we've heard on the ground, we believe this is largely under control, but we simply don't know for sure at this point. We believe it's too soon to declare this will be a bumper year in any way. What we can observe is that moving forward, should commodity prices remain at their current levels, obviously, our outlook going forward ought to be considerably stronger. I think for Crop Science specifically, one thing to keep in mind is that especially during the first half of the year, we do have some one-time effects. You'll remember we have a transitional sales agreement with BASF. On a year-on-year basis, this will cost us roughly EUR 100 million. We also have a one-time item, an older corn license that expires, and we had a regulatory loss of thiacloprid, a neonic in Europe last year. Those two elements combined will cost us approximately EUR 150 million-EUR 200 million.
Liam Condon
executiveSo that's roughly EUR 250 million to EUR 300 million, equating to around one and a half percentage points of growth, and we essentially have to absorb that — it's already baked into the 2% growth we're guiding for. Hopefully that gives you a somewhat clearer picture. For my part, I believe the larger effect from these elevated commodity prices, should they persist, will mostly show up in 2022, since we're able to reprice seed in August of this year. Naturally, the Brazilian pricing recovery is going to keep going, and a full season will benefit all of us, unlike this year, when seed pricing had already been set last August at a time when commodity prices were especially low.
Peter Verdult
analystThat’s really useful. Thanks.
Stefan Oelrich
executiveHi, Peter. It's Stefan. You asked about disclosing regional sales figures for our launch products. Normally we don't provide that, particularly when those products are still well below the threshold to count among our significant products. I assume you mean our three launches — Nubeqa, finerenone, and VERQUVO — all of which are really beginning to build momentum, Nubeqa in particular. What I can share is that the current sales split between Europe and North America stands at roughly 90%-10%. That's approximately the breakdown, and it's normal, since in Europe we're only generating some sales from Germany at present. Stay tuned. As the year progresses, I hope that at some point I'll be able to disclose Nubeqa as an important product so you can see those sales. Regarding Verquvo, sales so far are very small because we only started this month, but we now have Verquvo sales in the United States, which is our launch country. For finerenone, we expect to begin in the second half of the year. On your question about Xarelto China: the overall guidance we've provided for Xarelto does capture some of the risk we're seeing in China, notably a price risk that could arise given that we've lost exclusivity and nine generics are currently approved.
Stefan Oelrich
executiveSome of our sources indicate that the 10 mg Xarelto generic would be priced at roughly 80% of what we currently charge. It remains to be seen how much uptake generics will get in the market. Meanwhile, as you've observed, we weren't included in wave 4 of China's volume-based procurement, so that tender process is avoided for us during the first half of the year. We'll need to watch how the second round later this year unfolds, since we still carry the risk of being included there. That's essentially where things stand with XARELTO in China.
Peter Verdult
analystThanks, Stefan. To me it seems like you're taking a cautious approach with the guidance and, shall we say, building in a conservative assumption. Would that be fair to say?
Stefan Oelrich
executiveYeah. We believe those figures are achievable in China. Yes, that's a fair statement.
Peter Verdult
analystThanks.
Operator
operatorMr. Andrews has the next question.
Vincent Andrews
analystVincent Andrews from Morgan Stanley.
Operator
operatorKindly give your name and the firm you represent, and then go ahead with what you'd like to ask.
Vincent Andrews
analystHi, Vincent Andrews from Morgan Stanley. Liam, I wanted to follow up, maybe specifically on soy. I think the description was more soybean competition. I just wanted to unpack that a bit, since soy acres will be up and soy prices have risen a lot, but it also sounds like, for whatever reason, competition has increased despite that better backdrop. Is that because, just in the fourth quarter, you didn't have all the state registrations, so you couldn't properly market Xtend and people were looking to exploit that temporary vulnerability? Or is something else going on, like you're just not expecting to take part in the rise in soybean acres? Let me just start there.
Liam Condon
executiveThank you very much, Vincent, for that question. Regarding soybeans, I believe the key thing — as with all row crops here in the U.S. — is that the season runs from Q4 through Q3. So Q4 of 2020 through Q3 of 2021. In our portfolio, we faced a situation where, as you put it, an NGO challenge caused us to lose the registration for XtendiMax, a critical piece of our soybean system. Naturally, farmers care a great deal about this. When purchasing a system, they need assurance that every component will be obtainable. I think our regulatory team did an excellent job securing a new registration — a five-year registration — which was actually superior to the previous one. That didn't come through at the federal level until the end of October. We then had to work through the state-by-state process and obtain registration in each individual state, which took roughly two to three months. We wrapped that up in early January. Given the level of soybean prices, many farmers, of course, wanted to place their pre-season orders, and they needed to be 100% certain the product would be available. In that respect, we simply could not compete at the same level as a competitor who had all of its registrations in place.
Liam Condon
executiveWe just got off to a late start this season owing to the regulatory circumstances. At this point, everything we require is in our pipeline. We have XtendiMax and VaporGrip with the five-year registration. XtendFlex has been approved, and we expect it to be on at least 15 million acres this year. We're able to proceed with that now for the remainder of the season. The reality is that the first quarter of the selling season has been lost for us, and our sales are going to feel that impact. Such is the competitive dynamic. Moving forward to the next season, we're in right from the start. Our portfolio is full. We will be highly competitive. With our XtendFlex beans, we believe we're seeing a four-bushel per acre improvement. And naturally, we then have the added herbicide flexibility. We believe we'll be highly competitive, but we simply have to recognize that we missed out on the first quarter of the market season, and that is going to affect how we perform in soybeans this year.
Vincent Andrews
analystAlright, so as a quick follow-up, could you tell me what you're seeing on the seed production cost side this year? Does that act as a headwind to your profit guidance? And in the same vein, do you have any worries about raw material costs and crop protection, given that we're seeing reflation across the commodity complex — whether that's crude oil, derivatives, or whatever else? How do you feel about that for this year?
Liam Condon
executiveWhen it comes to Seeds COGS at the moment, we hedge our seed production. On Seeds COGS, no material headwinds are visible to us right now. Nothing has been flagged. I think we're in pretty good shape there. On crop protection, clearly from a raw material point of view, there is an increase in costs. This is actually primarily related to logistics, which is, of course, containers, airplanes. The market is extremely tight here. We haven't had any logistical issues to date. We simply have to pay more from a logistics point of view. Of course, we do our best within the, let's say, the ongoing organization through efficiency measures to somehow compensate for that. I wouldn't call it out as a material headwind for this year. We would expect to compensate that through our efficiency measures. Clearly there is a cost increase due to the tightness of logistics.
Vincent Andrews
analystThanks a lot.
Operator
operatorMr. Lunn is up next with a question. Kindly give your name first, then go ahead with what you'd like to ask.
Oliver Maier
executiveJo Walton.
Jo Walton
analystHi, this is Jo Walton calling from Credit Suisse. I have two questions — the first concerns pharma and the second concerns crop. Where pharma is concerned, I was hoping you might shed some light on the margin. In 2020, the margin came in at nearly 35%. This year it drops to 32%. Even after we strip out the EUR 150 million one-time Adempas item — which is under 1% of that — could you say a bit more about how large these launch investments you need actually are, or do you believe some of the cost savings achieved during COVID will have to be given up? Please just walk us through the cost on that. Turning to the crop side and looking a bit further ahead: you've said you lost out to your competitor as a result of your restrictions. Once farmers have tried that system, along with the genetics they can purchase with it, how easy do you think it will actually be to win those farmers back? I'm simply trying to gauge how straightforward it will be to reverse that competitive loss again next year.
Jo Walton
analystThanks.
Stefan Oelrich
executiveHi Jo, thanks for asking. To begin with, let me say that tight cost discipline remains in place through 2021, just as it was across 2020, and that's really necessary since we want to deliver a reasonable margin—a solid margin—even while putting substantial money into growth. Your question is the correct one. How much of that is going toward the launches? It represents a sizable investment, since we are bringing out three products simultaneously—VERQUVO, Nubeqa, and venetoclax—and two of those are in the North American market, where we previously had no cardiorenal presence. A significant expense is tied to this, and it is in fact larger than the 200 basis points you mention, with the remainder offset by the milestone payment for Adempas, which likewise equals 100 basis points. We also have some of the existing business, as we anticipate restarting customer-facing activities worldwide outside China, where things are currently still largely normal. Taken together, that all leads to the margin. This is something we communicated to you throughout all of last year as well.
Stefan Oelrich
executiveJust keep in mind that the VBP effect, which only began in the second quarter of last year, is now with us for the full year. Again, the takeaway is that we're putting money into growth—three launches happening simultaneously—and we have very strict, tight expense controls in place.
Liam Condon
executiveThanks, Jo, for that question. I’ll address it in terms of soybean competition, since I believe that’s what you were zeroing in on. First, with all this discussion about market share, it’s probably worth noting: last year we continued to hold the leading soybean system in the market, and this year our clear expectation is that we will remain the market leader. Just to make that clear right away. We also command the premium price, because we price based on value and we believe we deliver greater or better yield than anyone else in the market. As we indicated, we will give up some share simply because we’ve already lost the pre-season this year. Heading into the new year, or the next market season, which begins in Q4 2020, we are fully competitive. With the portfolio we have — XtendiMax with VaporGrip and XtendFlex — I think we’re in a great position at that point. We’ll have stabilized that entire market, and I would expect that we can then return to growth. Another important point from a soybeans perspective is that the U.S. is extremely important to us, of course, but Brazil is also very important. With Intacta 2, we’re on over 85 million acres in Latin America.
Liam Condon
executiveThis year we're bringing Intacta 2 Xtend to market — essentially the next generation of soybean technology in Brazil. Our expectations for it are high as well, and when you consider both together — XtendFlex in the U.S. and Intacta 2 Xtend arriving in Brazil — that's a strong place to start. Down the road, and we'll go into more detail on this at Capital Markets Day, we have the next-generation system, HT4, which delivers five herbicides. From a portfolio standpoint, I'd say we're in very good shape.
Jo Walton
analystThanks.
Operator
operatorOur next question is from Mr. Vosser. Kindly give us your name and the firm you represent, then go ahead with your question.
Richard Vosser
analystHello, and thank you for taking my question. This is Richard Vosser from JPMorgan. My first question is on Consumer Health. I'm thinking about the COVID pressures and how we ought to view those evolving over the course of the year. Could you give a bit more detail on what you've assumed there regarding the pressures on the cough and cold business in the back half of 2021? A weaker season is still expected — is that how you're looking at it? My second question concerns the asset sales. Obviously, yesterday you highlighted the Environmental Science asset sales. How should we think about the level of sales over the remainder of 2021 and the effect on the numbers? Thanks very much.
Heiko Schipper
executiveOkay, Richard, I’ll begin with the Consumer Health question. Yes, you’re correct — there is some volatility in the market. If we look back at 2020 first, you can see from our figures that a large part of our growth came from the very strong performance of our Nutritionals business, while on the other side, there was indeed a fairly significant decline in cough and cold. Still, overall we performed quite well — in fact, we grew ahead of the market. Then, thinking about 2021, and looking back at 2020 first, we see that during the first half of 2020, people were in fact stocking up on cough and cold products. We’ll face a difficult comparison in the first half, because especially in March there was this big stocking-up that occurred in 2020, and we’ll be cycling over that on top of already very weak demand, since there is very little flu. I expect the overall market in H1 to be quite challenging. Nutritionals will remain good, although we’ll also be cycling over higher numbers. In the second half, I actually do expect some growth to return in cough and cold as well, because I do expect there will be more movement again, thanks to the vaccines, particularly in some parts of the world.
Heiko Schipper
executiveI'd say the first half has a tough market backdrop. We already saw that in Q4, including from some of our peers. The second half is going to improve. For the year overall, you've seen the guidance we gave. We guided between 2 and 3, and we believe the market will likely come in a bit under that, so our goal is to keep outperforming the markets.
Liam Condon
executiveOkay, Richard, I’ll take your second question, which concerns the Environmental Science Professional business. That unit actually combines the professional business and the consumer business. It isn’t a single unit that’s up for sale. Sales expected to be impacted by the divestiture total roughly EUR 600 million. On the reporting side, we’ll determine during the next month when we will classify it as discontinued. For now, you should assume it remains within our full-year guidance, since it has been part of continuing operations up to this point. Our guidance includes the whole Environmental Science Professional business.
Operator
operatorOur next question is from Mr. Jackson. Kindly give your name and your company's name, then go ahead with your question.
Joel Jackson
analystHello, and thanks. This is Joel Jackson from BMO Capital Markets, and it's a good afternoon. I have a few questions, and I'll ask them one by one. First, returning to XtendFlex and the soybean competition: could you update us on the premium you're receiving for XtendFlex compared with Xtend? If we consider possibly losing some soybean share in 2021, it appeared you were guiding toward 20 million acres of XtendFlex, and now the figure you're citing is 15. Is that where you see part of the share loss—you're holding up in other Xtend products, but XtendFlex is really where you got less than you expected?
Liam Condon
executiveOkay, thank you very much, Joel. Regarding XtendFlex, our price is slightly higher than for Xtend. It's important to keep in mind that those pricing cards were set in August, which is normal for the season, and August was, again, a low point. Soybeans, I believe, were around $8 or $9 at that moment — pardon me, dollars — and today we're above $14. Obviously, if we were setting prices now, the cards would look different. Back then, when the market was also extremely intense, we had a modest premium for XtendFlex. The next chance to reprice, naturally, comes later this year in August, as we head into the following season. As for XtendFlex acres, the 20 million mentioned refers in fact to our production capacity for XtendFlex. Given the orders we have at present, we'd expect to be on at least 15 million acres. Everything will hinge on the split between XtendFlex and Xtend. Our order book is quite strong right now, and we can't say precisely what that ratio will be, but it should be at least 15 million acres of XtendFlex.
Joel Jackson
analystPardon me, and thanks for taking the question. This might be a topic that gets more attention at the Investor Day coming up in a couple of weeks. As you keep working to lessen some of the uncertainty surrounding glyphosate, when would it be sensible to examine whether value creation could result from separating Crop Science from the remaining businesses?
Liam Condon
executiveAre you asking when spinning off Crop Science would create value? Did I get that question right?
Joel Jackson
analystYes.
Werner Baumann
executiveOkay, thanks. We have a communicated strategy — a three-pronged approach for our businesses. Our portfolio is made up of our Pharmaceuticals business, our Consumer Health business, and our Crop Science business. There's no thought of divesting any of those businesses. What we've said is we're looking at divestitures below the divisional level, which we've done and will keep doing, actually, as part of our September 2020 communication. Most recently, as of yesterday, the communication to divest the Environmental Science Professional business. There could be more coming, but it will be below the divisional level.
Joel Jackson
analystI appreciate that.
Operator
operatorOur next question is from Keyur Parekh. Kindly give your name and your company's name, and then ask your question.
Analyst
analystGood afternoon, and thanks for taking my questions. I have two, please — one about crop and then one on the business more broadly. On crop, Liam, specifically, your guidance calls for 2% growth. I'm wondering whether you can break that down between what you assume for volume growth versus pricing versus any particular effect you might get from a hedging standpoint. Just to add to that, how would you characterize inventory levels in your crop protection business as you head into this season, both in the U.S. and in Brazil? That's question number one. Separately, I noticed in the annual report that came out this morning that the Supervisory Board held three extraordinary board meetings toward the end of last year. I was wondering whether you can add any incremental color. It's not very often that we see three extraordinary meetings at a supervisory board level within a relatively short period. What might those have been related to? Thank you.
Liam Condon
executiveOkay, thank you very much, Keyur. I'll begin with Crop Science. Regarding that 2%, and keeping this at a high level, what sits in the current assumptions is mainly growth driven by volume. Naturally, we'd be hoping that given the commodity price backdrop, we'd also see a favorable pricing picture. That said, as I noted before, we don't truly anticipate that in the seeds business during the first half of the year, since pricing had already been set last August. For crop protection, it comes down to how far farmers will stretch toward premium products in order to safeguard their harvests, and that also hinges on their view of where commodity prices are headed. At present it's mostly volume, with less growth from price, and hopefully there's upside potential on the pricing side should commodity prices remain strong. On inventory levels, I'd say the one area where we're seeing something that stands out or, let's say, isn't exactly flashing a green traffic light is probably Brazil, purely because the harvesting season has been delayed, and with that for soybeans, owing to weather conditions, especially in Mato Grosso, and along with that, naturally, a matching delay in planting for the Safrinha corn season.
Liam Condon
executiveWhat that really indicates is something I'd describe as a timing effect, and then a matter of inventory. We monitor it quite carefully. Around the world, and in Brazil too, we're entirely comfortable with where we stand. Brazil is the one spot I'd mention—simply because the season has been delayed—where we're keeping a very close eye on things. I'm fairly sure that once activity accelerates in Mato Grosso, all of that inventory will be cleared, but it's the only place I would call out.
Werner Baumann
executiveSure. I’ll pick up on the supervisory board meetings question. In fact, in the chairman’s report in the annual report, every one of them is listed individually. You’re able to review each single one. Near the end of the year, there was a fair amount of activity around two matters. First, naturally, our business is progressing. Second, AskBio became the topic of an extraordinary meeting. Naturally, as usual, near year-end, we discuss the plan for 2021 or the year after. In addition, we discussed strategy as well, since we had a somewhat different process in 2020 because of the high volatility of 2020 as a base year that would shape our midterm planning. That explains the sequence of meetings. On top of that, as you’ll understand, the year was extremely busy and extremely volatile, which is also mirrored in a substantially larger number of board meetings than the four regular ones we would typically hold.
Analyst
analystAppreciate it.
Operator
operatorOur following question is from Mr. Leuchten. Kindly give your name and the company you represent, then ask your question.
Michael Leuchten
analystHello, this is Michael Leuchten at UBS. Thanks for taking my question. Liam, I want to come back to you briefly for some clarification. You were quite clear about your pricing assumptions for the year, and I understand that. Is rebating something that might be a meaningful variable that could matter in 2021, given that you're unable to reprice your franchises? A question about your margin composition. Since your portfolio this year is a bit more skewed toward corn than soy, is the flat margin you're guiding to purely a result of the TSA and corn royalties going away and the effects of that, or is there something else we should factor in as we think about the moving parts for your margin? A quick question on the Pharmaceuticals margin. Is the CureVac agreement meaningful for the margin in 2021 and as we think about the trajectory into 2022? Thank you.
Liam Condon
executiveThanks, Michael. Regarding pricing and rebates, with the industry feeling as buoyant as it is overall, my view is that there's no reason for anyone to engage in heavy rebating of any kind this year. As always, we sit at a premium price. Given how good our products are, we typically establish the benchmark in the market when it comes to a premium price position. We devote a great deal of focus to the gross-to-net. No matter what happens on the rebate front, we'll be putting in serious effort to ensure our net pricing impact is positive overall this year. Turning to margin, naturally, beyond the quite substantial FX effect that Wolfgang described — one that hits us especially hard because of our U.S. exposure, above all in the first half of the year, given where U.S. dollar rates stand now compared with the first half of last year — you're right to flag the two, or rather three, items I raised: the corn royalties, which essentially flow one to one to the bottom line, and thiacloprid, the regulatory removal of thiacloprid in Europe. That's a product with very high margins. Those BASF sales are absent, and the same holds across all of the divisions within Bayer.
Liam Condon
executiveEvery bit of the savings we realized — those extraordinary savings from last year — can't simply carry over one for one into this year. We benefited from a lot of extraordinary COVID contingency measures, such as essentially zero travel. At some point this year, business is going to return to a more normal pattern. Automatically, some costs will rise. Naturally, we're facing some inflation. Naturally, given how the overall performance came out last year, incentive payouts are going to be relatively low for 2020. We'd expect them to normalize in 2021. All of these are things we need to offset through our synergies and efficiencies, but together they help explain why the margin doesn't improve further.
Stefan Oelrich
executiveHey Michael. Regarding CureVac, first I want to say how thrilled we are about the active part we're taking in what we hope will be a very active contribution toward bringing this pandemic to an end. What we have with CureVac isn't mainly a matter of financial considerations — it's far more about making the CureVac vaccine available to patients as quickly as we can across the world. So for that reason, please understand that right now we aren't providing financial details on this collaboration.
Michael Leuchten
analystAppreciate it.
Operator
operatorMr. Zechmann is up next with a question. Kindly give us your name and the firm you're with, and then go ahead with what you'd like to ask.
Gunther Zechmann
analystGood afternoon, this is Gunther Zechmann calling from Bernstein. I have one question, please, for Liam, regarding digital agriculture. Could you discuss what your value proposition looks like given the recent rise in soft commodity prices, whether you're rolling out price decks comparable to those in the crop input side of the business, and also share any acreage targets you may have rolled forward for the years ahead?
Liam Condon
executiveThanks, Gunther. Where acreage is concerned, perhaps as a starting point, penetration rose very sharply during the last year. As things stand, we now cover 150 million acres across 23 different countries. Naturally, the U.S. is by far the largest country for us. Brazil comes second, which does reflect the shape of our business. In our view, this progress has been fantastic, and outside parties have validated it as the deepest market penetration in digital ag by a wide margin. Continuing to speed that up is our goal as well. We aren't putting out a specific new additional target at the moment; we will be increasing. Going forward, our plan is to grow this acreage penetration substantially. For us, the entire business model is, naturally, about enabling our seeds and traits and crop protection business on one side. This simply lets us give growers far more precise recommendations, so they can raise their yield and also farm more sustainably, managing their costs better. Our business will benefit from this, but we likewise see a great opportunity for it to enable new business models. The best example here, I think, is our Carbon Farming Initiative, through which we incentivize farmers to sequester carbon in the soil.
Liam Condon
executiveIn this case, a digital platform truly serves as a core element of the entire business model—for tracking and verification, and in the end for connecting farmers to payments down the road as well. There's a great deal of potential here, in my view. We'll likely go into a bit more detail on this at CMD. It's a genuinely exciting piece of the portfolio.
Gunther Zechmann
analystAppreciate it. Could I ask a quick follow-up about acreage and pricing? Did I hear you mention 150 million acres? And is that figure for paid acres, if you don't mind clarifying?
Liam Condon
executiveRight, yes. That comes to 150 million acres under subscription. Our model includes both paid acres and a subscription option. Last year, we merged the U.S. incentive program — our Bayer PLUS program — with a FieldView subscription as well, and that produced a substantial rise in U.S. penetration too. It helped us lift market share and crop protection, especially in the U.S. during the past year. So it's a combination of paid and subscribed acres.
Gunther Zechmann
analystThanks a lot. Appreciate it.
Liam Condon
executiveAbsolutely. Thank you, Gunther.
Operator
operatorWe move to the following question, which is from Mr. Quigley. Kindly give your name, the company you represent, and then ask your question.
James Quigley
analystHi there, and thanks for taking my question. This is James Quigley with Morgan Stanley, and I have two, please. To begin with Nubeqa: you've only just launched the ARANOTE trial, so what's the thinking behind getting that study going? Clearly ARASENS was already underway, and ARANOTE wasn't kicked off alongside it. How are we meant to interpret that? Does it signal shrinking confidence in what ARASENS can deliver, or growing confidence in Nubeqa and how well it can compete more broadly? Second, could you help us size the COVID-related savings or cost avoidance you saw in 2020 — whether for the group overall or by division — just so we have some visibility into that, please. Thank you. Hello?
Stefan Oelrich
executiveOh, sorry about that. I believe I should begin my response over. James, let me start again. First, regarding ARASENS — I hope I can redo my answer. On ARASENS, perhaps as a starting point, we anticipate primary completion for this event-driven trial to occur in June of this year. Topline results ought to be available during the second half of the year. As a quick reminder, this trial examined Nubeqa in combination with androgen deprivation therapy and chemotherapy — docetaxel in this instance — in the metastatic setting. Why ARANOTE? In ARANOTE, we are evaluating darolutamide plus androgen deprivation therapy against placebo plus ADT in men who have metastatic hormone-sensitive prostate cancer. Unlike ARASENS, this setting does not include chemo. We understand that patients and physicians hold differing needs and preferences when it comes to treating patients across the various stages of the disease. As a result, we believe it makes complete sense to investigate darolutamide plus ADT versus ADT alone so that multiple treatment options exist for men with metastatic castrate-resistant prostate cancer. We think this makes complete sense within the product's life cycle. If we want to have the numbers reported by end of year or next year, we need to obtain solid data for the product, and we have great confidence in Nubeqa, so we are adding to it.
Wolfgang Nickl
executiveJames, I’ll give you some color on where the puts and takes sit for the company. A full ledger of the savings won’t be available — that would be too big a deal. I’ll give you two big categories, and Liam already kind of hinted toward it: travel and events. If you look at 2019, that’s roughly a EUR 600 million–EUR 700 million ticket for the total company. I won’t break it out by division — I think you’ll get the flavor. We’re at about half last year. There was almost no change, of course, in the first quarter. Of course, the following nine months were heavily impacted. In our guidance, we have modeled in a reassumption of traveling in the second half of the year. We’ll see how that works out. The second category is variable compensation plans. We have indicated before that it was up to EUR 500 million. It was somewhat below that — we just didn’t have the entitlements for. Again, we assume that that’s not recurring because we set up a plan where people can earn the entitlements. On many occasions, we were just pushing out projects and the like into the future. There were savings there as well.
Wolfgang Nickl
executiveCost increases did offset things to some degree as well. Freight costs, for example, rose across the board. We raised our donation level, for instance. Travel and events, along with variable compensation, make up the two major elements.
James Quigley
analystThanks a lot — that’s great.
Operator
operatorOur following inquiry is from Mr. Jones. Kindly give us your name along with your company's name, and then ask what you'd like to ask.
Tony Jones
analystThanks. Tony Jones from Redburn here. I think I’ve only got one question remaining, and it’s actually for Wolfgang. It’s about compensation again. On the STI payments, the annual report gives some really useful detail about what happened in 2020. Could you tell us what the target corridor ranges for EPS and free cash flow are for 2021? Thank you.
Wolfgang Nickl
executiveWe don’t disclose those upfront, as far as I know, but you should figure they are very tightly connected to the plans we share with the market.
Tony Jones
analystGot it. Thanks.
Oliver Maier
executiveHaley, I believe there's room for roughly one additional question.
Operator
operatorThe last question is from Mr. Friedrichs. Kindly give us your name, your firm's name, and then ask your question.
Falko Friedrichs
analystThanks. Falko Friedrichs here, from Deutsche Bank. Just one quick item, and it concerns the CureVac transaction. When it comes to mRNA, is that an area you're looking to keep developing and expanding past the pandemic — or is it simply a current priority as far as the COVID vaccine goes?
Stefan Oelrich
executiveThanks, Falko, for raising that — it's a really important question, since I believe mRNA has to be viewed within the broader picture of a cell and gene strategy. You've watched us take a very decisive step into this space by acquiring AskBio, along with BlueRock earlier and a few of the deals we generated in the past year. In our view, mRNA is a promising technology that might also work synergistically, in part, with certain activities we already have, extending past simply vaccinating against viral infections. It's a bit too early to discuss that here. We do consider this a very promising technology, yes.
Falko Friedrichs
analystAll right, thanks.
Oliver Maier
executiveAll right. That seems to be the final question. We appreciate everyone joining us today. Many thanks for spending your time with us, and we’ll be speaking with you again before long. Please stay safe, everyone. Thank you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.